More recently, a novel programmed cell death protein 1 inhibitor, sintilimab, has also preliminarily been shown to prolong recurrence-free survival following surgical resection in HCC patients with MVI [143]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.